Kazia Therapeutics Limited Stock Prediction and Forecast [KZIA]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 28 Oct 2025, 03:02 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Kazia Therapeutics Limited Stock Prediction and Forecast [KZIA]](https://i.ytimg.com/vi/UFkl0JnaMsU/hqdefault.jpg)
AI-generated source summary
The analysis focuses on Kazia Therapeutics (KZIA). Our system classified KZIA as hold/accumulate, assigning it a score of -0.350. KZIA is positioned at the upper end of a declining short-term trend. A breakout above $7.42 may slow the decline. There is possible 17.82% decline over three months, with returns between 33.78% down to 16.47%. The 12-month analysis expects about 64.75% decline. The price increased 4.58% on the last trading day, fluctuating by 12.90% between $6.51 and $7.35, making it a medium-risk stock. SVB Leerink rated KZIA as Market Perform, while H.C. Wainwright gave a Buy rating and there's a buy signal from 3-month Moving Average Convergence Divergence (MACD), but a sell signal given from a long term moving average. Key trading levels include resistance at $8.00 and support at $7.14. A suggested stop-loss is set at $6.94, a 5% decline.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.